Source: Bloomberg Avalanche Bio Drops 14%; Analysts Halve PTs on Wet AMD Update 2015-08-14 12:37:45.493 GMT By Cristin Flanagan (Bloomberg) -- Avalanche Biotech drops 14% in pre-mkt trading after announcing post-mkt yday plans to scrap a planned Phase 2b trial and instead initiate added preclinical studies t